A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Eluxadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms IBS-3002
  • Sponsors Furiex Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2017 Accoring to an Allergan media release, the company reported result of pooled subgroup analysis of two phase III trials (IBS-3001 and IBS-3002).
    • 10 Jul 2017 Accoring to an Allergan media release, the result of pooled subgroup analysis of two phase III trials (IBS-3001 and IBS-3002) was published in the American Journal of Gastroenterology in Jun 2017.
    • 22 Mar 2017 Results of pooled post-hoc analysis of two phase III trials (IBS-3001 and IBS-3002) published in the Alimentary Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top